Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study
| Autor: | Sonia Navas, Inmaculada Castillo, Maria José Rua, M. Ruiz-Moreno, Maria Dolores García-Novo, Vicente Carreño, Maravillas Santos |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Hepatitis C virus Biopsy Alpha interferon Pilot Projects Hepacivirus medicine.disease_cause Gastroenterology Polymerase Chain Reaction Interferon Internal medicine medicine Humans Hepatitis Antibodies Child Interferon alfa Retrospective Studies Body surface area Hepatitis Hepatology medicine.diagnostic_test business.industry Infant Alanine Transaminase medicine.disease Hepatitis C Recombinant Proteins Liver Liver biopsy Child Preschool Immunology Chronic Disease Interferon Type I RNA Viral Female business medicine.drug |
| Zdroj: | Hepatology (Baltimore, Md.). 16(4) |
| ISSN: | 0270-9139 |
| Popis: | Twelve children with chronic non-A, non-B hepatitis were entered in a pilot trial of recombinant interferon-α. Although all the children had hepatitis C virus RNA in serum, only five had antibodies against this virus. Children received 3 MU/m2 body surface area interferon-α 3 times/wk for 6 mo; they were followed for 24 mo, including the therapy period. One child was dropped from the study, so the results are from the 11 children who completed the study. At the end of the therapy period, 36% of the children had normal ALT levels; this percentage increased to 90% at mo 15 of follow-up. Thereafter, relapse occurred in five children; thus ALT normalization was observed in 5 of 11 children at the 24th month. Moreover, two different ALT patterns were found: HCV antibody—negative children had significant peaks of ALT levels with respect to the basal samples (p < 0.05) until the third month of the therapy; these levels later decreased. In contrast, HCV antibody—positive children had slight fluctuations of ALT until normal levels were reached. At the end of treatment, three children had HCV RNA; one demonstrated a rebound in ALT levels. Finally, histological activity had decreased significantly in the second liver biopsy specimen in all children. In summary, interferon treatment in children with chronic hepatitis C may be helpful, although these results should be confirmed in controlled trials. (HEPATOLOGY 1992;16:882–885.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text